Targeting of CCL2 and CCR2 might be a potential treatment of osteoarthritis (OA); in vivo findings from a murine OA model indicated that selective targeting of CCL2/CCR2, rather than CCL5/CCR5, was a viable therapeutic strategy (Raghu et al., 2017). The gene discussed is CCL5; the disease is osteoarthritis.